Sign in
4

Changes in Ownership

Allogene Therapeutics, Inc. Filed Acc 0001209191-19-039728

Chief Technical Officer acquired 27,816 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
MOORE ALISON Chief Technical Officer 2019-06-28 Option exercise +27,816 $2.27 $63,142 65,373 D
Derivatives
MOORE ALISON Chief Technical Officer 2019-06-28 Option exercise · Option to Purchase Common Stock (Right to Buy) −27,816 815,856 D
Loading xslF345X03/doc4.xml…